The point of it is that there's always pretty much a race between getting the product safely developed in the patient population for focus and getting it on the market as quickly as possible, so that there's still some time to recoup the cost of the product development. So you know often if you're ...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login